AzTrials
AzTrials

KeloidsEarly Phase 1NCT07531056

Comparison Of Effectiveness Of Intralesional Injectioms Of 5 Flourouracil Alone Verses Its Cpmbination With Cryotherapy In The Treatment Of Keloids

A Early Phase 1 study testing Cryotherapy will be done followed by intralesional injection of 5-fluorouracil and Intralesional 5-fluorouracil in people with Keloids, run by Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan at 1 site in Pakistan.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to learn how well intralesional 5 fluorouracil with cryotherapy works to treat keloids as compared to intralesional 5 fluorouracil alone on keloids. It will also learn about the safety of both these treatments. Read more about this study

Who is it for?
Ages 18 to 50 years
Conditions the study is for
Keloids
What is being tested?
Cryotherapy will be done followed by intralesional injection of 5-fluorouracil and Intralesional 5-fluorouracil
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
88 participants
Where
1 sitePakistan
Study dates
22 Dec 2025to 20 Sep 2026
Phase
Early Phase 1
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Patients willing to participate in the study
  • Patients of age group of 18 -50 years.
  • Patients having symptomatic keloids i.e., having pain, pruritus, restriction of movement, scar tension or disfigurement.

Who cannot join

  • :• Pregnant women or lactating women
  • Patients with history of hepatic, renal, cardiac diseases or chronic diarrhea.
  • Patients on immunosuppressant medications due to other diseases
  • Patients having myelosuppression checked by CBC.
  • Patient taking warfarin.
  • Patients with history of hypersensitivity to 5FU.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Pakistan1 site, 1 recruiting
  • CMH Bahawalpur

    Chak Eighty-seven -Twelve Left

    Areeba Sadia, +923336881616, areebasadiahadia@gmail.com

    Recruiting

Other trials in Pakistan

About this study

Official title: A Randomized Controlled Trial Comparing The Effectiveness And Safety Of iIntralesional 5 Flourouracil Monotherapy Verses 5 Flourouracil Combined With Cryotherapy; In The Treatment Of Keloid Scars

The goal of this clinical trial is to learn how well intralesional 5 fluorouracil with cryotherapy works to treat keloids as compared to intralesional 5 fluorouracil alone on keloids. It will also learn about the safety of both these treatments. The main questions it aims to answer are:

  • What well does cryotherapy followed by intralesional 5 fluorouracil (5FU) work to treat keloids as compared to 5 fluorouracil (5FU) alone?
  • What is participant's satisfaction when treated with cryotherapy followed by intralesional 5 fluorouracil (5FU) as compared to 5 fluorouracil (5FU) alone?
  • What skin problems do participants have when treated with cryotherapy followed by intralesional 5 fluorouracil (5FU) and 5 fluorouracil (5FU) alone? Researchers will compare cryotherapy followed by intralesional 5 fluorouracil (5FU) with 5 fluorouracil (5FU) alone to see how well both work.
Read more

Participants will be divided into two groups:

For Group A: Cryotherapy will be done at lesion site followed by intralesional 5FU every 3 weekly.

For Group B: Intralesional 5FU will be given at lesion site every 3 weekly. Keloids will be assessed at the start of trial and then after 12 weeks of treatment.

Read the detailed description

The rationale of this study is to find cost-effective treatment regime of cryotherapy with intralesional 5 fluorouracil for keloids. Investigator aim to compare how effective is the combination of cryotherapy followed by intralesional 5 fluorouracil (5FU) as compared to 5 fluorouracil (5FU) alone in the treatment of keloids.

88 patients with keloids consulting the dermatologist in the hospital OPD will be included in the trial after application of the mentioned inclusion and exclusion criteria. After informed consent, a dermatologist will explain the required details of the procedure to the patients and give them their required treatment plan. Participanys will be randomized into two groups by lottery method. Demographic data like age, gender, location, duration, number of keloids, Fitzpatrick skin type, family history of keloids, keloid symptoms (pain, itching or disfigurement), previous treatments (topical steroids, topical silicone sheet or cream, cryotherapy, surgical excision, intralesional steroids or none) will be recorded along with the baseline photograph and rating of severity score based on DSS score. For Group A, Cryotherapy will be done by a spray mini-cryogun ( Brymill B800 Cry-Ac 3 dispenser) using liquid nitrogen targeted at the lesion from the distance of 1 cm and freeze thaw cycles of 30 seconds will be repeated till the lesion freezes to the level of its contact with skin. With larger lesions 2cm2 area will be targeted in a stepwise manner to ensure homogenous cryotherapy of the entire lesion. Local anaesthesia will be given before the cryotherapy with bupivacaine injection, as it relives pain up to 72 hours. 30 minutes after the cryotherapy session intralesional injection of 5 fluorouracil 50mg/ml 0.75ml mixed with 0.25ml triamcinolone acetonide 10mg/ml for every 2cm2 of keloid using a 30-gauge needle with a 3cc syringe. Not to exceed 150 mg/ml in a single session. The injection will be pushed gently into the lesion to the point of inducing swelling and blanching of lesion. The lesion shall be bandaged for 01 hour after the injection.

Group B will be advised local anaesthesia with bupivacaine followed intralesional injection of 5 fluorouracil 50mg/ml 0.75ml mixed with 0.25ml triamcinolone acetonide 10mg/ml for every 2cm2 of keloid. Not to exceed 150 mg in a single session. Oral pain killer will be prescribed for 3 days usage after injection in both treatment groups. Treatment in both groups will be repeated every 3 weeks for 4 sessions in total. If there will be large necrotic area after the previous session, it will be allowed to heal before the next session.

A blinded independent medical observer will perform clinical assessment at the end of 12 weeks treatment period using the DKS score for all 88 patients.

Participant satisfaction will be checked by Patient Global Impression-improvement scale, which is a seven-point scale used by patient to report the overall improvement in their disease with treatment as 1: Very much improved, 2: Much improved, 3: Minimally improved, 4: No change, 5: Minimally worse, 6: Much worse and 7: very much worse. Side-effects like severe pain, blistering, infection and eschar formation will be noted in both groups within the 12 weeks treatment period starting from the 1st hour post injection. A blinded dermatologist from our department will keep record of the side-effects.

Conditions
Keloids
Being tested
Cryotherapy will be done followed by intralesional injection of 5-fluorouracil, Intralesional 5-fluorouracil
Keywords
Keloids, Intralesional injectioms, 5-FU
Medical subject headings
Keloid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cryotherapy will be done followed by intralesional injection of 5-fluorouracilDrug

    Cryotherapy will be done followed by intralesional injection of 5-FU diluted in steroid, this will be done in phases. Not more than 150mg 5-FU will be used during each session. Session will be repeated after every 3 week for 6 months.

  • Intralesional 5-fluorouracilDrug

    intralesional 5-FU will be given in phases. sessions will be repeated after every 3 weeks for 6 months

Study groups in NCT07531056
Study groupRoleWhat they receive
Cryotherapy followed by intralesional injection of 5-FUExperimentalNot described
Receives: Drug: Cryotherapy will be done followed by intralesional injection of 5-fluorouracil
Intralesional injection of 5-FUActive comparatorNot described
Receives: Drug: Intralesional 5-fluorouracil

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Side-effects like severe pain, blistering, infection and eschar formation will be noted in both groups within the 12 weeks treatment period starting from the 1st hour post injection

    Measured: From enrollment to the end of treatment at 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Apr 2026
  2. Study start22 Dec 2025
  3. Primary completion20 Sep 2026 (estimated)
  4. Study completion20 Sep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
88 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07531056
Sponsor's protocol ID
1587/EC/14/2025
Status last verified
Apr 2026
First submitted
1 Apr 2026
Last updated
24 Apr 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Cryotherapy will be done followed by intralesional injection of 5-fluorouracil and Intralesional 5-fluorouracil in people with Keloids, run by Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan at 1 site in Pakistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Side-effects like severe pain, blistering, infection and eschar formation will be noted in both groups within the 12 weeks treatment period starting from the 1st hour post injection (time frame: From enrollment to the end of treatment at 12 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in